Recombinant Human Cripto-1 Protein(Fc Tag)

Catalog Number: PDMH100311

Note: *Centrifuge before opening to ensure complete recovery of vial contents.*

Description

Species	Human
Source	Mammalian-derived Human Cripto-1 proteins Leu31-Ser169,with an C-terminal Fc
Mol_Mass	40.2 kDa
Accession	P13385
Bio-activity	Not validated for activity

Properties

Purity	> 90% as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 ℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Data



SDS-PAGE analysis of Human Cripto-1 proteins , 2μg/lane of Recombinant Human Cripto-1 proteins was resolved with SDS-PAGE under reducing conditions , showing bands at 40 KD

Background

For Research Use Only

Recombinant Human Cripto-1 Protein(Fc Tag)

Catalog Number: PDMH100311

Cripto/TDGF1 is a member of the epidermal growth factor (EGF)-Cripto , Frl-1 , and Cryptic (CFC) family. EGF-CFC family member proteins share a variant EGF-like motif , a conserved cysteine-rich domain , and a C-terminal hydrophobic region. Before gastrulation , Cripto is asymmetrically expressed in a proximal–distal gradient in the epiblast , and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. These proteins play key roles in intercellular signaling pathways during vertebrate embryogenesis. Mutations in Cripto/TDGF1 can cause autosomal visceral heterotaxy. Cripto/TDGF1 is involved in left-right asymmetric morphogenesis during organ development. Cripto signalling is essential for the conversion of a proximal–distal asymmetry into an orthogonal anterior–posterior axis. The mechanism of inhibitory effects of the Cripto includes both cancer cell apoptosis , activation of c-Jun-NH(2)-terminal kinase and p38 kinase signaling pathways and blocking of Akt phosphorylation. Thus , Cripto is a unique target , and Immunohistochemistry to Cripto could be of therapeutic value for Human cancers.

For Research Use Only